# Travere Medical Affairs

> Travere Global Medical Affairs is dedicated to scientific exchange, including sharing up\-to\-date scientific insights \& resources with HCPs\.

Generated by Yoast SEO v28.3, this is an llms.txt file, meant for consumption by LLMs.

## Pages
- [Rare Kidney Disease News](https://medicalaffairs.travere.com/rare-kidney-disease-news/)
- [Podcasts](https://medicalaffairs.travere.com/podcasts/)
- [Home](https://medicalaffairs.travere.com/)
- [Sparsentan FSGS clinical trials](https://medicalaffairs.travere.com/fsgs/sparsentan-clinical-trials/)
- [Meetings \& Events](https://medicalaffairs.travere.com/meetings-events/)

## Events
- [Genetic Metabolic Dietitians International \(GMDI\) Annual Conference 2024](https://medicalaffairs.travere.com/meetings-events/gmdi-2024/)
- [American Society of Nephrology \(ASN\) Kidney Week 2026](https://medicalaffairs.travere.com/meetings-events/asn-kidney-week-2026/)
- [National Kidney Foundation \(NKF\) Spring Clinical Meetings 2026](https://medicalaffairs.travere.com/meetings-events/nkf-2026/)
- [ISN \& Travere: A New Dawn for IgAN – 
Redefining What is Possible with Sparsentan](https://medicalaffairs.travere.com/meetings-events/travere-isn-webinar-new-dawn-igan-sparsentan/)
- [19th International Conference on Endothelin \(ET\-19\)](https://medicalaffairs.travere.com/meetings-events/et-19-conference-2025/)

## Publications
- [Sparsentan Versus Irbesartan in Pediatric Patients With FSGS](https://medicalaffairs.travere.com/publications/sparsentan-irbesartan-pediatric-fsgs-duplex-study/)
- [Review of the Clinical, Humanistic, and Economic Burden of Focal Segmental Glomerulosclerosis](https://medicalaffairs.travere.com/publications/review-clinical-humanistic-economic-burden-fsgs/)
- [Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice](https://medicalaffairs.travere.com/publications/practical-considerations-sparsentan-igan-clinical-practice/)
- [Long\-Term Outcomes in IgA Nephropathy](https://medicalaffairs.travere.com/publications/long-term-outcomes-in-iga-nephropathy/)
- [KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy \(IgAN\) and Immunoglobulin A Vasculitis \(IgAV\)](https://medicalaffairs.travere.com/publications/kdigo-2025-igan-guideline/)

## Posters
- [How Does Nephrotic\-Range Proteinuria Differ From Nephrotic Syndrome in Focal Segmental Glomerulosclerosis \(FSGS\)? ](https://medicalaffairs.travere.com/congress-materials/glomcon-2026-infographic-duplex-double-blind-baseline-proteinuria-posthoc/)
- [In DUPLEX, Patients With Focal Segmental Glomerulosclerosis \(FSGS\) Reached Low Proteinuria More Often With Sparsentan vs Irbesartan Regardless of Baseline Proteinuria](https://medicalaffairs.travere.com/congress-materials/glomcon-2026-visual-abstract-duplex-double-blind-baseline-proteinuria-posthoc/)
- [In DUPLEX, Patients With Focal Segmental Glomerulosclerosis \(FSGS\) Reached Low Proteinuria More Often With Sparsentan vs Irbesartan Regardless of Baseline Proteinuria](https://medicalaffairs.travere.com/congress-materials/glomcon-2026-poster-duplex-double-blind-baseline-proteinuria-posthoc/)
- [The Effect of Sparsentan on Proteinuria and Urinary Inflammatory and Profibrotic Biomarkers by Baseline Proteinuria Strata in SPARTAN Study Participants With IgA Nephropathy](https://medicalaffairs.travere.com/congress-materials/glomcon-2026-poster-spartan-biomarkers-baseline-proteinuria-posthoc/)
- [PROTECT Post Hoc Analysis: Efficacy of Sparsentan vs Irbesartan in Patients With IgA Nephropathy ≤12 Months vs \>12 Months From Kidney Biopsy](https://medicalaffairs.travere.com/congress-materials/glomcon-2026-poster-protect-time-from-biopsy/)

## Abstracts
- [Prevalence of Cerebrotendinous Xanthomatosis \(CTX\) Among Patients Diagnosed With Juvenile\-OnsetIdiopathic Bilateral Cataracts](https://medicalaffairs.travere.com/abstracts/aapos-2023-prevalence/)
- [Dietary Goals and Current Challenges in the Management of Classical Homocystinuria: Insights From Multinational Real\-World Experience](https://medicalaffairs.travere.com/abstracts/dietary-goals-and-current-challenges-in-the-management-of-classical-homocystinuria-insights-from-multinational-real-world-experience/)
- [Pegtibatinase, an Investigational Enzyme Replacement Therapy for the Treatment of Classical Homocystinuria: Initial Results from the Phase 1/2 Compose Study](https://medicalaffairs.travere.com/abstracts/pegtibatinase-an-investigational-enzyme-replacement-therapy-for-the-treatment-of-classical-homocystinuria-initial-results-from-the-phase-1-2-compose-study/)
- [A Longitudinal Study of Cognitive Function in Classical Homocystinuria Demonstrates Distinct Deficits in Inhibitory Control](https://medicalaffairs.travere.com/abstracts/a-longitudinal-study-of-cognitive-function-in-classical-homocystinuria-demonstrates-distinct-deficits-in-inhibitory-control/)
- [Population\-based incidence estimates of classical homocystinuria using the Genome Aggregation Database \(gnomAD\)](https://medicalaffairs.travere.com/abstracts/population-based-incidence-estimates-of-classical-homocystinuria-using-the-genome-aggregation-database-gnomad/)

## MSL
- [Sushma Shiravanthe](https://medicalaffairs.travere.com/msl/keith-latham/)
- [Darshika Desai](https://medicalaffairs.travere.com/msl/lauren-dwyer-2/)
- [Kendal Burstad](https://medicalaffairs.travere.com/msl/lauren-dwyer/)
- [Monte Overcast](https://medicalaffairs.travere.com/msl/mark-mills/)
- [Jeremy Chen](https://medicalaffairs.travere.com/msl/alex-willcockson/)

## MSL Territories
- [Intermountain \(WMSL08\)](https://medicalaffairs.travere.com/msl-location/intermountain-wmsl08/)
- [Northern California \(WMSL07\)](https://medicalaffairs.travere.com/msl-location/northern-california-wmsl07/)
- [Southern California \(WMSL06\)](https://medicalaffairs.travere.com/msl-location/southern-california-wmsl06/)
- [Texas \(WMSL05\)](https://medicalaffairs.travere.com/msl-location/texas-south-wmsl05/)
- [Heartland \(WMSL04\)](https://medicalaffairs.travere.com/msl-location/texas-north-wmsl04/)

## Episodes
- [Evolving Management of FSGS: Proteinuria and Clinical Data](https://medicalaffairs.travere.com/podcasts/rare-kidney-disease-show/fsgs-management-proteinuria-clinical-data/)
- [Travere and KDIGO Podcast Collaboration \- Conversations in Nephrology: Treating FSGS: From Steroids to Dual Endothelin Angiotensin Receptor Antagonists and What Comes Next](https://medicalaffairs.travere.com/podcasts/kdigo/treating-fsgs-steroids-deara/)
- [Travere and KDIGO Podcast Collaboration \- Conversations in Nephrology: Proteinuria First: Managing What Matters in FSGS](https://medicalaffairs.travere.com/podcasts/kdigo/proteinuria-first-fsgs/)
- [Travere and KDIGO Podcast Collaboration \- Conversations in Nephrology: The Podocyte Problem: Understanding FSGS](https://medicalaffairs.travere.com/podcasts/kdigo/podocyte-problem-fsgs/)
- [KDIGO Podcast](https://medicalaffairs.travere.com/podcasts/kdigo/)

## RKD News
- [Advancing Care in Pediatric FSGS: Insights from the DUPLEX Clinical Trial](https://medicalaffairs.travere.com/rare-kidney-disease-news/advancing-care-in-pediatric-fsgs/)
- [Advancing Care in FSGS: A New Era in Treatment and Clinical Understanding ](https://medicalaffairs.travere.com/rare-kidney-disease-news/fsgs-a-new-era-in-treatment/)
- [FSGS in Focus: Drivers of Progression and the Patient Burden](https://medicalaffairs.travere.com/rare-kidney-disease-news/fsgs-disease-progression-and-humanistic-burden/)
- [Exploring Clinical Trial Endpoints in FSGS: Spotlight on Proteinuria](https://medicalaffairs.travere.com/rare-kidney-disease-news/fsgs-clinical-trial-endpoints-proteinuria/)
- [Engaging Patients for Better Outcomes: Informed Care for IgA Nephropathy](https://medicalaffairs.travere.com/rare-kidney-disease-news/informed-healthcare-for-patients-with-igan/)

## Optional
- [Sitemap index](https://medicalaffairs.travere.com/sitemap_index.xml)